


# Riboflavin, Oxygen and Light

Sabine Kling, PhD, Farhad Hafezi, MD, PhD



Universität Zürich




# Corneal Cross-linking


Increasing corneal stiffness to stop the progression of keratoconus



de-epithelialization





365 nm,  
3mW/cm<sup>2</sup>



Photosensitizer  
30 min

# Different techniques for cross-linking


- chemically (e.g. glutaraldehyde)
- ionizing radiation (e.g.  $\gamma$  ray,  $e^-$  ray)
- photo-chemically (e.g. **UV-light** + photosensitizer)



REF. Spoerl E. Exp Eye Res 1998

# Advantages of photo-chemically induced cross-linking


**X** no DNA mutations  
due to radiation



**X** no health hazard due  
to chemicals



**✓** penetration depth is  
adjustable




# **Selection of the photosensitizer and wavelength**

# Selection of wavelength and photosensitizer

- Increasing the absorption of UV-light
- Photosensitizer excitation

## Riboflavin:




+ moderate UV-energy  
+ moderate penetration depth  
+ not absorbed from DNA  
→ used for CXL

**365 nm**

+ high UV-energy  
- low penetration depth  
- highly absorbed from DNA  
→ DNA damage

+ moderate penetration depth  
- lower UV-energy  
→ less effective

# Photosensitizer



TIME SCALES (sec)	
1	$10^{-15}$
2	$10^{-7} - 10^{-5}$
3	$10^{-14} - 10^{-11}$
4	$10^{-9} - 10^{-7}$
5	$10^{-10} - 10^{-8}$
6	$10^{-3} - 100$
7	$10^{-3} - 100$




**Long-lived triplet state: allows for chemical reactions**



**generation of reactive oxygen species**

# Reaction mechanism

## Type I mechanism:





radicals

**Little** oxygen consumption.


reactive oxygen  
species

## Type II mechanism:




**High** oxygen consumption.

# Oxidation of the extracellular matrix



- Formation of new cross-links
- Increased mechanical stiffness of the corneal tissue

# Cross-linking of collagens and / or proteoglycans?



REF. Zhang Y. J Biol Chem 2011

- cross-links:**
- among collagens
  - among proteoglycans
  - between collagens and proteoglycans

# Riboflavin


- **concentration**
- **osmolality**
- **application modes**
- **photo-degradation**

# Function of riboflavin

- **Generation of radicals in the presence of UV and oxygen**
- **Protection of the endothelium and crystalline lens from UV damage**

# Safety of CXL treatment


UV-fluence  
 $5.4 \text{ J/cm}^2$



with riboflavin:  
UV-fluence  
 $\sim 0.18 \text{ J/cm}^2$

Normal cornea:



- high UV absorption  
→ protection of the endothelium and crystalline lens



Thin cornea:


- low UV absorption
- higher UV dose at the endothelium  
→ risk of endothelial damage  
→ risk of cataract

# UV absorption of riboflavin





- **The higher the riboflavin concentration, the stronger the UV absorption.**
- **The stronger the UV absorption, the less penetration into deeper stromal layers.**

# Viscosity of the riboflavin solution and dropping frequency



- **The higher the viscosity, the thicker the riboflavin film on the corneal surface.**
- **The thicker the riboflavin film, the less UV energy reaches the corneal stroma.**

# Photodegradation of riboflavin



# Different riboflavin solutions

## EPI-OFF

### Hypertonic:

- riboflavin 0.1 g, dextran 500 (VibeX)

### Isotonic:

- 0.1% Riboflavin, 1.1% HPMC (MedioCROSS D)

### Hypoosmolar / hypotonic:

- 0.1% Riboflavin, 1.1% HPMC (MedioCROSS M)
- 0.1% B<sub>2</sub>-riboflavin-5-phosphate, 0.9% sodium chloride

### Accelerated:

- riboflavin 0.1 g, HPMC (VibeX Rapid)

## EPI-ON

### Hypoosmolar:

- 0.25% Riboflavin, 1.2% HPMC, 0.01% Benzalkonium Chloride (MedioCROSS TE)

### Accelerated:

- 0.25% Riboflavin, HPMC, BAC (Paracel)

### Iontophoresis:

- 0.1% Riboflavin + enhancers (RICROLIN®TE)




# Osmolality

**=> considers total concentration of penetrating solutes *and* non-penetrating solutes**

*Osmolality is a property of a particular solution and is independent of any membrane.*

$$\text{osmolarity} = \sum_i \varphi_i n_i C_i$$

osmotic coefficient  $\varphi_i$   
number of particles into which a molecule dissociates  $n_i$   
solute molar concentration  $C_i$




**human cornea = 300 mOsm/L**

# Tonicity

=> considers total concentration of *only* non-penetrating solutes

=> considers external pressure difference (unilateral pressure)

*Tonicity is a property of a solution in reference to a particular membrane.*




Dextran T500 cannot penetrate the denuded stroma. If prepared as hyperosmolar solution => hypertonic => stromal dehydration

Riboflavin can penetrate the denuded stroma. If prepared as hyposomolar solution => hypotonic => stromal swelling

# Administration modalities


## Dropping in intervals of 3-5 min on the corneal surface

- Distribution determined by the Fick's law of diffusion



## Iontophoresis-assisted application


- Distribution determined by the applied voltage



# Oxygen

- **availability**
- **consumption**

# Oxygen dependency



- **Fast oxygen depletion (UV on):**  
10-15 seconds ( $3\text{mW}/\text{cm}^2$ )  
2-5 seconds ( $30\text{mW}/\text{cm}^2$ )
- **Slow oxygen replenishment (UV off):**  
3-4 minutes

REF. Kamaev P. IOVS 2012

**No stiffening effect of cross-linking in the absence of oxygen.**

REF. Richoz O. IOVS 2013

# Oxygen diffusion into the corneal stroma

**Fick's law of diffusion:**


$$\frac{\partial_{concentration}}{\partial_{time}} = -diffusion\ coefficient \cdot \frac{\partial^2_{concentration}}{\partial_{distance^2}}$$

corneal thickness

Depends on the partial pressure of oxygen in the air and could be modified by increasing/decreasing:

- atmospheric pressure
- percentage of oxygen

# The effect of oxygen reduction on biomechanical stiffening




**Oxygen reduction by -50% leads to a decreased stiffening effect by -50%.**

# 3 essential components for CXL:



- UV-light absorptionA
- excitation of oxygenA
- excitation of riboflavinA
- oxidation of the extracellular matrixA



# Clinical implications


irradiation time



## Accelerating CXL treatment

### Bunsen-Roscoe law of reciprocity:

*A certain biological effect is directly proportional to the total energy dose, irrespective of the administered regime.*



**corneal stiffening ~ UV fluence (?)**



irradiation time


# Accelerated CXL



**Idea:** Shorter irradiation time & higher UV irradiance.

## Clinical outcome:


- efficiently stops keratoconus progression
- no difference to standard CXL*



REF. Tomita M. JCRS 2014

## Experimental quantification:

- less efficient



REF. Wernli J. IOVS 2013

REF. Hammer A. IOVS 2014



oxygen availability

## Pulsed CXL




**Idea:** Interrupt UV-irradiation periodically to allow oxygen diffusion into the cornea

⇒ Increase the effect of CXL

### Clinical outcome:


- efficiently stops keratoconus progression
- no difference to standard CXL*



REF. Mazzotta C.  
J Ophthalmol 2014

### Experimental quantification:

- less efficient



REF. Kling S. ESCRS 2015



oxygen availability

# Trans-epithelial CXL




- is less effective than standard CXL

REF. Leccisotti A. JRS (2010)

Similar **UV absorption** and **oxygen consumption** in epithelial cells and stroma.

however:

no stiffening effect in the epithelium



REF. Kolozsvari L. IOVS (2002)



→ comparable to standard CXL in a deeper stromal layer



UV fluence

# CXL efficacy as a function of corneal thickness

- higher oxygen availability
- larger proportion of the stroma is cross-linked



- lower oxygen availability
- smaller proportion of the stroma is cross-linked

→ stronger CXL in thinner corneas

UV fluence

# Complications of CXL in thin corneas



**100  $\mu\text{m}$  murine cornea**  
treated with 5.4 J/cm<sup>2</sup>



*REF. Kling S.  
CXL congress (2014)*

**404  $\mu\text{m}$  human cornea**  
treated with 5.4 J/cm<sup>2</sup>





*REF. Soeters N. J Pediatr  
Ophthalmol Strabismus (2011)*



# A model to predict the stiffening effect of CXL

Tomorrow



**Patient-specific adaptation of  
CXL treatment parameters**

# Conclusions

- **CXL requires 3 main components: photosensitizer (riboflavin), UV-light (365nm, 5.4J/cm<sup>2</sup>) and oxygen.**
- **Riboflavin is required to initiate the generation of additional cross-links – but also to protect the endothelium and crystalline lens from damage.**
- **Oxygen is rapidly consumed during CXL. Current protocols are limited by the speed of oxygen diffusion into the stroma.**
- **CXL protocols may be *clinically* effective, even if they have a reduced *experimental* stiffening effect.**

**Thank you  
for your attention**